43 filings
6-K
GLPG
Galapagos NV
20 Dec 19
Gilead submits new drug application to U.S. Food and Drug Administration under priority review for filgotinib for rheumatoid arthritis treatment
6:01am
6-K
GLPG
Galapagos NV
9 Dec 19
Galapagos completes recruitment of NOVESA trial in systemic sclerosis
10:11am
6-K
GLPG
Galapagos NV
26 Nov 19
Current report (foreign)
6:51am
6-K
GLPG
Galapagos NV
19 Nov 19
Galapagos receives transparency notification from Wellington Management Group LLP
6:00am
6-K
GLPG
Galapagos NV
14 Nov 19
Current report (foreign)
6:00am
6-K
2ytn2jvjpw jo
12 Nov 19
Current report (foreign)
6:15am
6-K
xrs2cni6yjlc2tff9yw
6 Nov 19
Current report (foreign)
4:24pm
6-K
us643
4 Nov 19
Current report (foreign)
6:00am
6-K
20pw9fwmzpalh
29 Oct 19
MOR106 clinical development in atopic dermatitis stopped for futility
6:00am
6-K
okmu3v
28 Oct 19
Galapagos receives transparency notification from Wellington Management Group LLP
6:01am
6-K
ys2xm8gutc
25 Oct 19
Solid third quarter 2019 performance with strong balance sheet for continued R&D growth
5:00pm
6-K
4gyh1n ox1yp33k
23 Oct 19
Current report (foreign)
10:19am
6-K
tkwitz
11 Oct 19
Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks In Finch 1 and Finch 3 Studies In Rheumatoid Arthritis
6:00am
6-K
78zsck0gyry2np5lgci2
8 Oct 19
Galapagos receives transparency notification from Wellington Management Group LLP
6:01am
6-K
qeoot
25 Sep 19
Current report (foreign)
10:50am
6-K
4z4ahi
23 Sep 19
Current report (foreign)
6:00am
6-K
fmm t96n98jkiudsd
20 Sep 19
Current report (foreign)
4:07pm
6-K
akewb o2lbojqhsnh
19 Sep 19
Current report (foreign)
5:26pm
6-K
mzt6q1t sjl4de
5 Sep 19
Current report (foreign)
5:26pm
6-K
4yxjphq96dj 92ywtp
5 Sep 19
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
5:24pm